Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Receivables: 2017-2024

Historic Receivables for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $1.7 million.

  • Cidara Therapeutics' Receivables rose 9.54% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 72.02%. This contributed to the annual value of $1.7 million for FY2024, which is 87.96% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Receivables of $1.7 million as of FY2024, which was down 87.96% from $14.1 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Receivables registered a high of $22.3 million during FY2020, and its lowest value of $1.7 million during FY2024.
  • Over the past 3 years, Cidara Therapeutics' median Receivables value was $11.4 million (recorded in 2022), while the average stood at $9.1 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Receivables soared by 222,650.00% in 2020, and later slumped by 87.96% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Receivables (Yearly) stood at $22.3 million in 2020, then tumbled by 63.38% to $8.2 million in 2021, then surged by 40.18% to $11.4 million in 2022, then climbed by 23.11% to $14.1 million in 2023, then tumbled by 87.96% to $1.7 million in 2024.